Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

NCT00706706 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
105
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer